One patent. A documented chemical lineage.
The leaf is not the end of the chemistry. It can be the beginning.
The debate over kratom frequently draws a bright line between the “natural leaf” and chemically modified opioid compounds. U.S. patent application US20230250098A1, Kratom Opioid Derivatives for the Treatment of Alcohol Use Disorder, shows why the line is not so simple.
Its researchers purchased commercial kratom powder, isolated naturally occurring alkaloids, described the synthesis of related compounds, and tested those compounds at opioid receptors. These are separate, documented stages of the same research program—not a claim that every finished compound was made from one specific extracted batch.
The public-policy question is what additional opioid-active compounds can be developed from the chemical building blocks supplied by a plant that remains widely available.
Read US20230250098A1 on Google Patents →The issue in 30 seconds
What the patent establishes
The source material
It started with powdered kratom leaves
“Mitragynine was extracted from the powdered leaves”
US20230250098A1, “Isolation of Mitragynine from Mitragyna speciosa (Kratom).” View source →
The patent identifies the purchased product as Red Indonesian Micro Powder from Moon Kratom in Austin, Texas. The researchers describe processing 500 grams of kratom powder and isolating multiple alkaloids from the resulting extract.
Amounts are the isolated quantities reported in the patent, not concentrations typical of all kratom products. The patent also reports a crude extract and other minor alkaloids. Reaction instructions are intentionally omitted here.
The important finding is not merely that kratom contains alkaloids. The researchers isolated them from an ordinary commercial plant product and used kratom alkaloid chemistry as the foundation for further drug-development research.
From plant chemistry to new compounds
What they developed beyond the natural leaf
The patent states that the structures of naturally occurring paynantheine and speciogynine were used as scaffolds for analog synthesis. Figure 2 identifies hydroxylated and pseudoindoxyl derivatives.
These compounds should not all be described as “mitragynine converted into new drugs.” The patent's highlighted new analogs primarily use paynantheine and speciogynine structures. That makes the broader point more significant: mitragynine is not the only kratom alkaloid that can serve as a starting framework for opioid-active chemical development.
Experimental pharmacology
These were not merely new names. Researchers measured opioid-receptor activity.
Figure 3 reports testing at mu (MOR), delta (DOR), and kappa (KOR) opioid receptors. The assays evaluated binding and functional responses, including G-protein-linked signaling and beta-arrestin recruitment.
Why this matters: binding to an opioid receptor does not automatically mean a substance is an agonist. Functional signaling tests help determine whether it activates the receptor, partially activates it, or instead blocks activity. The patent reports distinct profiles for different derivatives; they are not interchangeable.
Two especially revealing compounds
7-Hydroxyspeciogynine (7OH-SPG): The patent reports functional opioid-receptor activity, including mu-opioid G-protein signaling. Its mu-opioid potency was lower than that of 7-hydroxymitragynine in the cited cell assay. The researchers also linked its effects on alcohol consumption in mice at least partly to delta-opioid receptor signaling.
7-Hydroxypaynantheine (7OH-PAYN): The patent likewise reports opioid-receptor signaling and preclinical effects on alcohol consumption, with lower mu-opioid potency than 7-hydroxymitragynine in the reported comparison.
The patent describes mixed agonist and antagonist profiles among other compounds. It would be inaccurate to call every tested substance a full mu-opioid agonist. The stronger, scientifically defensible conclusion is that the plant-derived chemical family includes newly developed compounds with measurable opioid agonist activity.
The patent did not simply draw new molecules on paper. It measured their effects on opioid-receptor signaling and tested selected compounds in animals.
Why develop these compounds at all?
The stated purpose was to investigate potential medicines for alcohol use disorder. Researchers sought compounds that could influence opioid pathways associated with alcohol consumption while reducing unwanted effects associated with mu-opioid activation.
That is legitimate pharmaceutical research, but it also demonstrates the chemical versatility of kratom alkaloids. The patent explicitly considers derivatives as potential active pharmaceutical ingredients. Its claims about therapeutic promise are not evidence of FDA approval or proven human safety.
The patent's mouse studies and receptor assays are preclinical evidence, not proof that these substances will become approved medicines or commercial street drugs.
What does this mean for laws that protect “natural kratom”?
Preserving the leaf while regulating only a short list of finished molecules leaves an important question unanswered: how should laws address new opioid-active compounds developed from alkaloids found in that leaf?
This patent demonstrates that natural kratom alkaloids can be isolated, studied, and chemically modified into additional receptor-active compounds. It does not prove that manufacturers of illicit products are using the patented methods, or that any particular derivative is being sold.
But lawmakers considering a natural-versus-synthetic distinction should understand that a botanical source and a chemically modified finished product can belong to the same chemical lineage. The finished substance may be different; its starting scaffold may still come from the plant.
The regulatory challenge is not limited to what kratom leaves contain today. It includes what chemists can develop from the alkaloids they contain.
What this patent proves—and what it does not
It documents: commercial kratom powder as a source material; isolation of mitragynine, paynantheine, speciogynine, and speciociliatine; synthesis of related analogs; and experimental opioid-receptor pharmacology for selected compounds.
It does not establish: that all derivatives were produced from the same isolated batch; that every derivative is an opioid agonist at every receptor; that every substance is commercially sold; or that kratom leaf can be casually converted into these compounds outside a chemistry laboratory.
Those limits do not diminish the central finding. They make it more precise—and harder to dismiss.
Primary documentation
Read the patent for yourself
US20230250098A1 — Kratom Opioid Derivatives for the Treatment of Alcohol Use Disorder
Published August 10, 2023.
Look for the experimental section titled “Isolation of Mitragynine from Mitragyna speciosa (Kratom)”, Figure 2 (alkaloid structures and analog synthesis), Figure 3 (opioid-receptor characterization), and the discussion of 7-hydroxyspeciogynine and 7-hydroxypaynantheine.
Open the complete patent on Google Patents →This article reports the patent's disclosed research and distinguishes experimental findings from broader policy implications. It does not reproduce laboratory synthesis instructions. Patent publication is not FDA approval or evidence of commercial distribution.